Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

The Global Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies) was valued US$ 370.4 million in 2017 and is projected to exhibit a CAGR of 4.8% over the forecast period (2018 - 2026). 

Scopolamine is a prescription drug used to treat muscle spasms, Parkinson’s disease, vomiting, irritable bowel syndrome, nausea, and dizziness that often accompanies motion sickness.

Although scopolamine is a completely legal drug prescribed by a physician, it has been used for illicit purposes in various economies such as UK and Colombia. Commonly scopolamine is also called as Devil’s Breath or burundanga.

It has made headlines around the world, from Canada to Australia to Colombia, and there were at least 1,200 known cases reported in 2012 of the drug being used to force people – including politicians – into doing illegal things.

Use of scopolamine in Alzheimer's disease may prove useful as a diagnostic or staging test in the evaluation of the cholinergic system in dementia, which provides opportunities to the researchers to explore application of these drugs for other neurological disorders, which in turn is driving the market growth over the forecast period.

Browse 19 Market Data Tables and 23 Figures spread through 151 Pages and in-depth TOC on "Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies) - Global Forecast to 2026"

To know the latest trends and insights related to scopolamine market, click the link below:

Manufactures in scopolamine market are focused on developing new generics through partnerships to strengthen the product portfolio. For instance, in 2017, Perrigo Company plc. and its co-development partner Aveva Drug Delivery Systems, Inc., launched scopolamine 1.5 mg transdermal system patch, generic equivalent to GlaxoSmithKline’s Transderm Scop (scopolamine 1.5 mg),

This transdermal system patch is indicated for prevention of nausea and vomiting in adults associated with motion sickness and recovery from anesthesia and/or opiate analgesia and surgery.

The annual U.S. market sales/revenue for Transderm Scop were around US$ 158 million in the 12 months ending in May 2017.

Key takeaways of the Scopolamine Market:

  • The global scopolamine market is expected to expand at a CAGR of 4.8% during the forecast period (2018–2026), owing to high adoption of scopolamine in surgeries and post-operative recovery.
  • Patches segment hold major market share among dosage forms due to utilization of these patches during surgeries to prevent hyper salivation and to speed-up the recovery from post-operative and anesthesia induced vomiting and nausea
  • Major players operating in global scopolamine market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.